Inflammation Drives a Distinct Subtype of Depression With Unique Symptoms and Treatment Response

Depression affects hundreds of millions globally and is a leading cause of disability and suicide. A central challenge is its profound heterogeneity—patients share diagnostic labels but not underlying biology, making standardized treatment unreliable. This review by Andrew H. Miller, MD, synthesizes decades of translational and clinical research to argue for the formal recognition of an inflammatory subtype of major depressive disorder (MDD).

The evidence begins epidemiologically: meta-analyses consistently show elevated mean levels of TNF, IL-1β, IL-6, and CRP in depressed cohorts versus controls. Yet only approximately 25% of depressed patients show CRP >3 mg/L, the threshold associated with elevated inflammatory risk. This means the group-level signal is driven by a biologically distinct minority. Postmortem brain studies corroborate peripheral findings, revealing activated microglia, macrophage infiltration, and elevated inflammatory signaling molecules in brain parenchyma and cerebrospinal fluid. Multiomics analyses further identify TNF, IL-1β, and STAT3 as primary upstream regulators of depression-associated molecular signatures across brain and peripheral tissues.

This inflammatory subtype maps onto a specific symptom cluster dominated by neurovegetative features—anhedonia, motivational deficits, fatigue, psychomotor slowing, and disrupted sleep and appetite—collectively resembling evolutionary 'sickness behavior.' Neuroimaging studies using fMRI and PET demonstrate that inflammatory stimuli (IFN-alpha, endotoxin, typhoid vaccination) reliably reduce ventral striatal activation during reward anticipation and disrupt connectivity between subgenual anterior cingulate cortex, nucleus accumbens, and ventromedial prefrontal cortex. Depressed patients with elevated CRP show the same corticostriatal disruptions, which correlate with anhedonia severity. Mechanistically, inflammation reduces dopamine availability in the striatum and increases basal ganglia glutamate via cytokine-mediated impairment of astrocytic glutamate reuptake (EAAT2 downregulation), both contributing to motivational and psychomotor deficits.

The treatment implications are clinically significant. Elevated inflammatory biomarkers predict poor response to SSRIs but a relatively better response to catecholaminergic agents (nortriptyline, bupropion), ketamine, and electroconvulsive therapy. Anti-cytokine therapies—most notably the TNF antagonist infliximab—preferentially improve anhedonia in patients with elevated CRP (>3 mg/L), and a controlled trial showed infliximab significantly increased effort-based motivation and altered ventral striatal circuitry. Levodopa similarly reversed corticostriatal reward circuit deficits and reduced anhedonia selectively in patients with high inflammation. Minocycline and other anti-inflammatory agents also show promise in biomarker-enriched populations.

The paper calls for refining diagnostic nosology to incorporate this mechanism-based subtype, enabling precision psychiatry. Future research should clarify whether myeloid-dominant versus lymphoid-dominant immune profiles represent disease stages or distinct subtypes, and validate composite biomarker panels for clinical deployment. Limitations include the cross-sectional nature of many cited studies, reliance on peripheral CRP as a proxy for central neuroinflammation, and the lack of large-scale randomized trials using immune biomarker-based patient selection.